1. Scrip
  2. >>Business
  3. >>Deals

FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why

 
• By Jessica Merrill

Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

• Source: Shutterstock

Federal Trade Commission Deputy director of the Bureau of Competition Rahul Rao said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.

Key Takeaways

  • FTC deputy director of the Bureau of Competition Rahul Rao discussed some of the agency’s recent actions on pharma deals.

  • More scrutiny of pharma deals has stemmed, in part, from “pain points” in the market and the economy, he said

“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects of that consolidation. We are seeing higher prices

More from Deals

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.